You are here

Amgen

Novartis touts effectiveness, safety of autoimmune drug copies

Novartis touts effectiveness, safety of autoimmune drug copies

Yahoo/Reuters

autoimmune disease

Flag link:

Could an old Amgen-developed RA drug make CAR-T treatments safer?

Could an old Amgen-developed RA drug make CAR-T treatments safer?

Fierce Biotech

cytokine release syndrome

Flag link:

Migraine Breakthrough: Not So Fast

Migraine Breakthrough: Not So Fast

Forbes

monoclonal antibodies

Flag link:

Amgen's $3.9B Neulasta to face U.S. biosim 'in the coming weeks' with Mylan approval

Amgen's $3.9B Neulasta to face U.S. biosim 'in the coming weeks' with Mylan approval

Fierce Pharma

Flag link:

Amgen to ramp up early-stage immuno-oncology with 2 MD Anderson deals

Amgen to ramp up early-stage immuno-oncology with 2 MD Anderson deals

Fierce Biotech

MD Anderson Cancer Center

drug development

Small-Cell Lung Cancer

Flag link:

FDA stalls yet another Herceptin copycat, issuing response letter to Amgen/Allergan

FDA stalls yet another Herceptin copycat, issuing response letter to Amgen/Allergan

Endpoints

complete response letter

Flag link:

ASCO Preview: Are Combo Treatments With Cancer-Killing Viruses Worth The Cost?

ASCO Preview: Are Combo Treatments With Cancer-Killing Viruses Worth The Cost?

Forbes

Flag link:

Thanks to lower-than-expected price, ICER backs Amgen's Aimovig—but only after other meds fail

Thanks to lower-than-expected price, ICER backs Amgen's Aimovig—but only after other meds fail

Fierce Pharma

Flag link:

With $460B in borrowing capacity, will any of the Big-20 biopharmas go after one of the top-5 takeover targets?

With $460B in borrowing capacity, will any of the Big-20 biopharmas go after one of the top-5 takeover targets?

Endpoints

Gilead Sciences

Flag link:

Biopharma M&A: You Ain’t Seen Nothing Yet

Biopharma M&A: You Ain’t Seen Nothing Yet

Barron's

Gilead Sciences

Flag link:

Up-and-coming Pfizer, AbbVie drugs set to threaten Amgen, Celgene: analyst

Up-and-coming Pfizer, AbbVie drugs set to threaten Amgen, Celgene: analyst

Fierce Pharma

Flag link:

Will Amgen’s migraine win and 5th thumbs-up for Prolia drive enough growth? Nope, says analyst

Will Amgen’s migraine win and 5th thumbs-up for Prolia drive enough growth? Nope, says analyst

Fierce Pharma

Flag link:

Amgen And Avalere Reports Reveal "Upside Down" Payer Biosimilar Realities

Amgen And Avalere Reports Reveal "Upside Down" Payer Biosimilar Realities

Biosimilar Development

drug development

Flag link:

Amgen, AbbVie 'ahead of the crowd' in fighting payers' latest assault on copay coupons

Amgen, AbbVie 'ahead of the crowd' in fighting payers' latest assault on copay coupons

Fierce Pharma

Flag link:

Migraine prevention drug could be worth $1 to $2 billion over next five years: Wall Street analyst

Migraine prevention drug could be worth $1 to $2 billion over next five years: Wall Street analyst

CNBC

Flag link:

AstraZeneca drops Amgen-partnered solid tumor drug

AstraZeneca drops Amgen-partnered solid tumor drug

Fierce Biotech

Flag link:

Amgen’s new migraine drug will cost 30 percent less than Wall Street expected

Amgen’s new migraine drug will cost 30 percent less than Wall Street expected

Stat

Flag link:

Amgen's Aimovig won its first-in-class migraine nod. Will payers step up to the $6,900 price?

Amgen's Aimovig won its first-in-class migraine nod. Will payers step up to the $6,900 price?

Fierce Pharma

Flag link:

Pfizer’s Epoetin Alfa Biosimilar Approved by FDA

Pfizer’s Epoetin Alfa Biosimilar Approved by FDA

RAPS.org

Flag link:

Are These Disappointing Drugs Back on Track to Billions?

Are These Disappointing Drugs Back on Track to Billions?

Motley Fool

PCSK9 inhibitors

Flag link:

Pages